Results 211 to 220 of about 24,552 (280)

Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy [PDF]

Lin‐Lin Cao, Hao Song, Cuicui Wang, Qiang Xu, Chenyang Zhou, Maogui Hu, Jing Ming, Guolin Wu, Dandan Fan, Yuanyuan Feng, Xinchen Wang, Hailiang Chu, Kaiyang Ding   +12 more
openalex   +1 more source

BTK Gene Mutation [PDF]

, 2020
openaire   +1 more source

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation. [PDF]

J Med Chem
Hopkins BT, Marx IE, Vandeveer HG, Nevalainen M, Basile R, Bajrami B, Choi CK, Grater RJ, Gu C, Hoemberger M, Kadakia E, Kapadnis SK, Liu Y, Ma B, Magee T, Metrick CM, Mingueneau M, Muste CA, Parker Harp CR, Prince RJ, Santoro JC, Schulz J, Sciabola S, Tang H, Wang T, Meissner R, Bohnert T.   +26 more
europepmc   +1 more source

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy

Stefano Molica, David Allsup
openalex   +2 more sources

BTK Inhibitor M7583 [PDF]

, 2020
openaire   +1 more source

Endovascular Treatment Modalities for Infrapopliteal Artery Disease: A Bayesian Network Meta-Analysis with Exploratory Evaluation of Retrievable Scaffold Therapy. [PDF]

Cardiovasc Intervent Radiol
Saleem M, Tariq MH, Mudassar M, Brar A, Usman A, Jibbran A, Tariq F, Zaitoun A.   +7 more
europepmc   +1 more source

Discovery of Covalent Ligands with AlphaFold3. [PDF]

J Am Chem Soc
Shamir Y, Gabizon R, Rogel A, Lin DY, Andreotti AH, London N.   +5 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors

Jorge J. Castillo, Francesco Autore, Neil L. Berinstein, Andrew R. Branagan, Meletios Α. Dimopoulos, Carlos Fernández de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C. Minnema, Lugui Qiu, John F. Seymour, Josephine M. I. Vos, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, M. Lia Palomba   +18 more
openalex   +1 more source

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]

Curr Hematol Malig Rep
Benrashid S, Woyach JA.
europepmc   +1 more source